It has been about a month since the last earnings report for DexCom (DXCM). Shares have lost about 7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the ...
DexCom DXCM shares soared 7.3% in the last trading session to close at $102.14. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...
DexCom's DXCM shares have risen 6.9% since Tuesday last week, while yesterday’s after-market movement took the rally to nearly 8%. Last week, the company presented a positive picture for its ...
San Diego’s Dexcom delivered mixed financial results for its fourth quarter, as the continuous glucose monitor maker navigated COVID-19 headwinds and increased costs that weighed on its bottom line.
Earlier on November 25, Evercore ISI initiated coverage of DexCom with an In Line rating and $68 price target. While ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose monitoring (CGM) market. A strong third-quarter 2025 performance and a series ...
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240605396939/en/ Diabetes management goes hands-free as ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback